Kymera Therapeutics, Inc.
Industry Group: Pharmaceuticals
Country/Region: United States of America
Identifier: NAS:KYMR
Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of, differentiated medicines that address health problems and that meaningfully improve patients’ lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, TYK2, and IRAK4.
ESG Risk Rating
Ranking
Industry Group (1st = lowest risk)
Pharmaceuticals 703 out of 847
Universe
Global Universe 12920 out of 14948
What are the ESG Risk Ratings?
Notice: The information is provided as is, for informational, non-commercial purposes only, does not constitute investment advice and is subject to conditions available in our Legal Disclaimer. They are not directed to, or intended for distribution to or use by India-based clients or users and their distribution to Indian resident individuals or entities is not permitted. Usage of this information is not permitted in any way, unless otherwise agreed in writing. By way of exception, usage of this information is permitted to the non-India based rated subjects, limited to a single reference to the score on the rated subject’s sustainability webpage or CSR report, mentioning Sustainalytics as a source. For referencing Sustainalytics please consult the Company Guide.
Industry Comparison
Company | ESG Risk Rating | Industry Rank |
---|---|---|
BrightGene Bio-Medical Technology Co., Ltd. |
26
Medium
|
218 out of 847 |
Agios Pharmaceuticals, Inc. |
26.6
Medium
|
248 out of 847 |
BioArctic AB |
27.2
Medium
|
276 out of 847 |
PharmaResearch Co., Ltd. |
29
Medium
|
355 out of 847 |
Kymera Therapeutics, Inc. |
36.4
High
|
703 out of 847 |
For corporate professionals interested in direct competitor insights
Sustainalytics' Peer Performance Insights gives an in-depth analysis of your company's ESG strengths and weaknesses compared to your competitors and industry performance. These insights can be used to identify areas of ESG improvement to help inform future management decisions that align with your organization's sustainability goals.
Our Approach to Calculating ESG Risk
The ESG Risk Ratings measure a company's exposure to industry-specific material ESG risks and how well a company is managing those risks.
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues. Our exposure score takes into consideration subindustry and company-specific factors such as its business model.
Kymera Therapeutics, Inc.'s Exposure is Medium
Management
Management refers to how well a company is managing its relevant ESG issues. Our management score assesses the robustness of a company's ESG programs, practices and policies.
Kymera Therapeutics, Inc.'s Management of ESG Material Risk is Weak